Drugs & Targets Lifebit, gen-t, and Omica.bio partner to diversify genomic research July 21, 2023Vol.49 No.29
Drugs & Targets FDA grants priority review to zolbetuximab for gastroesophageal junction adenocarcinoma July 07, 2023Vol.49 No.27
Drugs & Targets European Commission approves Opdivo + platinum-based chemotherapy in NSCLC indication June 30, 2023Vol.49 No.26
Drugs & Targets FDA establishes Oncology Quality, Characterization and Assessment of Real-World Data Initiative June 30, 2023Vol.49 No.26
Drugs & Targets LoxiGen awarded three-year STTR grant to develop therapy for drug-resistant TNBC June 30, 2023Vol.49 No.26
Drugs & Targets FDA approves Talzenna with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer June 23, 2023Vol.49 No.25
Drugs & Targets FDA establishes pilot program to reduce risks associated with cancer biomarker laboratory developed tests June 23, 2023Vol.49 No.25
Drugs & Targets FDA grants priority review to capivasertib + Faslodex for advanced HR-positive breast cancer June 16, 2023Vol.49 No.24
Drugs & Targets FDA accepts sBLA for Keytruda in combination with chemotherapy in liver cancer indication June 09, 2023Vol.49 No.23
